What is BPC 157?
BPC 157 is an an anti-ulcer peptide. BPC is shorthand for “Body Protecting Compound.” It’s actually natively present in gastric acid in small quantitites so it’s not a “foreign” substance. Peptides are short chains of amino acids.
BPC 157 may promote tendon and ligament healing, oppose the negative effects of NSAIDS like aspirin, and rescue damage from inflammatory bowel disease. BPC 157 is also a promising therapeutic for periodontal disease, at least in animal models.
The viability of BPC 157 as a treatment for ulcerative colitis and multiple sclerosis is being assessed in clinical trials in Croatia1. The Croatian medical literature refers to the petide as PL14736.
While there is some promising studies about BPC 157, please bare in mind that biomedical research in some eastern European countries (e.g., Russia) is not as rigorous as elsewhere:
In the 20th century, Russian biomedical science experienced a decline from the blossom of the early years to a drastic state. Through the first decades of the USSR, it was transformed to suit the ideological requirements of a totalitarian state and biased directives of communist leaders. Later, depressing economic conditions and isolation from the international research community further impeded its development.
What’s The Optimal BPC 157 Dosage?
There is no “typical” BPC 157 dosage. This is an investigational peptide with few reported studies conducted in humans. However it is reassuring that BPC 157 is already present in your gastric juice in small amounts.
Anecdotally, some people have reported benefits at dosages in the 1-10 ug/kg range. The upper end of that range – 10 ug is one one-hundredth of a milligram.
You should know that peptides are extremely sensitive to environmental conditions. In particular, light (UV) and heat will cause peptides to degrade. Peptides actually spontaneously degrade at an extremely slow rate even in perfect environmental conditions. Peptide stability is an active area of research.
Multiple Sclerosis and BPC 157
Why Use A Gastric Peptide To Treat A Neurological Disorder?
At first glance it might seem bizarre to treat multiple sclerosis patients with a gastric peptide.
Medicine has historically treated the brain like an isolated black box disconnected from the body. In a way, the west inherited this worldview from Descartes. But there was a radical shift in the last decade with recognition of the brain-gut axis.
The brain-gut axis is the relationship between the GI tract and the central nervous system. Biochemical signaling takes place between gut and brain. It has been clear from the start that your brain affects your gastrointestinal system. For example, anxiety can upset your stomach. What wasn’t so clear was that this signaling also works the other way around – your environment in your gut affects your brain.
Multiple sclerosis is an autoimmune disorder where overzealous immune cells attack the myelin sheath in the brain.
BPC 157 is being explored as a potential treatment for Multiple Sclerosis because BPC maintains gastrointestinal mucosa integrity which has downstream effects on the brain. BCP 157 also modulates serotonergic and dopaminergic systems.
BPC 157 Effects
BPC 157 has been noted to have these properties:
- Neuroprotective effects (protects the brain from insult and injury)
- Promotion of healing 2
- Correction of nitric oxide system dysfunction 2
- Upregulation of VEGFR23.
- Reduction of bleeding and thrombocytopenia
BPC 157 and Angiogenesis
BPC 157 seems to boost angiogenesis – but the mechanism is not so clear. One study investigated the potential pro-angiogenic mechanisms of BPC 157 3. They found that BPC 157 increased vessel density both in the petri dish and in live animals. The authors noted enhanced vascular expression of vascular endothelial growth factor receptor 2 (VEGFR2). In addition to increasing gene expression, BPC 157 enhanced internationalization of VEGFR2 and intracellular activation of VEGFR2-Akt-eNOS.
BPC 157 And Nitric Oxide
Nitric Oxide (NO) is a gas that acts as a signaling molecule in the body with a rapid half-life. NO has a vasodilatory effect, meaning that it tends to open up blood vessels. Vasodilation tends to be good for cognitive health since hypertension negatively impacts cognitive function and impairs cerebral blood flow. Taking hot baths also has vasodilatory effect which may stave off cognitive decline. (See: Sauna bathing is inversely associated with dementia and Alzheimer’s disease in middle-aged Finnish men.4)
BPC 157 Experience Reports
Reddit user striker_321 reported:
BPC-157: This compound is fascinating, and has a wide range of effects. I took ~150mcg orally and sublingually for a month hoping that it would help heal a back injury I had sustained. It did not help with this ROA, but my first several doses felt strong, like something was being “reset”. Those changes were not felt after that time, but even several weeks after taking an extended amount of time off, my baseline seems to be permanently raised. I feel calmer in general and it is easier to focus on mundane tasks. Additionally, my digestive system which was prone to occasional issues has also been operating much smoother after this trial. Recently, I have tried ~10 days of using 150mcg with a DMSO carrier on my back injury, and it seems to be having the effects I was going for when I started taking the oral dose. I have decided to do a cycle of injections near the injury site to see if I can further assist the healing process. Be advised, this substance causes significant angiogenesis, which is a double edged sword: it helps the healing process, but could “supercharge” cancer growth if you have pre-existing cancer. I am relatively young, and had necessary check-ups and a blood panel prior to experimenting with this substance. Check pub med with the keyword “BPC-157” as well as a general reddit search to learn more.
- Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. Journal of pharmacological sciences. 2008; 108(1): 7-17. ↩
- Djakovic Z, Djakovic I, Cesarec V, et al. Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME. World journal of gastroenterology. 2016; 22(41): 9127-9140. ↩ ↩2
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of molecular medicine (Berlin, Germany). 2016; (): . ↩ ↩2
- Laukkanen T, Kunutsor S, Kauhanen J, Laukkanen JA. Sauna bathing is inversely associated with dementia and Alzheimer’s disease in middle-aged Finnish men. Age and ageing. 2016; (): . ↩
- Zemba M, Cilic AZ, Balenovic I, et al. BPC 157 antagonized the general anaesthetic potency of thiopental and reduced prolongation of anaesthesia induced by L-NAME/thiopental combination. Inflammopharmacology. 2015; 23(6): 329-36. ↩
- Castillo C, Asbun J, Escalante B, Villalón CM, López P, Castillo EF. Thiopental inhibits nitric oxide production in rat aorta. Canadian journal of physiology and pharmacology. 1999; 77(12): 958-66. ↩